RGS17
RGS17 (Regulator of G protein signalling 17) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.
Overview
Regulates G protein-coupled receptor signalling cascades, including signalling via muscarinic acetylcholine receptor CHRM2 and dopamine receptor DRD2. Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits, thereby driving them into their inactive GDP-bound form. Binds selectively to GNAZ and GNAI2 subunits, accelerates their GTPase activity and regulates their signalling activities.
Open Targets scores its association with cancer at 0.53 (direct and indirect evidence; datatypes literature 0.92, genetic association 0.66).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · RGS17 (Regulator of G protein signalling 17) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.
- 1 · What it is
RGS17 (Regulator of G protein signalling 17) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.
- 2 · What goes wrong in cancer
Regulates G protein-coupled receptor signalling cascades, including signalling via muscarinic acetylcholine receptor CHRM2 and dopamine receptor DRD2.
- 3 · How drugs use it
No product in this corpus aims at RGS17 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:14088 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9UGC6 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000091844 (association with cancer (MONDO_0004992) 0.53; per-cancer scores at or above 0.5: prostate cancer 0.52 (GraphQL API, CC0))
Biology
Regulates G protein-coupled receptor signalling cascades, including signalling via muscarinic acetylcholine receptor CHRM2 and dopamine receptor DRD2. Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits, thereby driving them into their inactive GDP-bound form. Binds selectively to GNAZ and GNAI2 subunits, accelerates their GTPase activity and regulates their signalling activities. Negatively regulates mu-opioid receptor-mediated activation of the G proteins. Location: Membrane; Synapse, synaptosome; Nucleus; Cytoplasm (UniProt). Locus 6q25.2 (HGNC).
- Prostate cancer: Open Targets association 0.52 with prostate cancer (MONDO_0008315)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: none stated by the sources. Evidence tier "association-only" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"RGS17" OR ABSTRACT:"RGS17" OR TITLE:"regulator of G protein signaling 17" OR ABSTRACT:"regulator of G protein signaling 17" OR TITLE:"Regulator of G protein signaling 17" OR ABSTRACT:"Regulator of G protein signaling 17" OR TITLE:"RGSZ2" OR ABSTRACT:"RGSZ2" OR TITLE:"RGS-17" OR ABSTRACT:"RGS-17") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RGS17, not a curated reading list.